article Open AccessTop 1% cited

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine · 2010 · Vol. 363(8) · pp. 711–723

F. Stephen Hodi✉(Harvard University)Steven O’Day(Angeles Clinic and Research Institute)David F. McDermott(Hadassah Medical Center)Robert WeberJeffrey A. Sosman(Vanderbilt University Medical Center)John B.A.G. Haanen(The Netherlands Cancer Institute)René González(University of Colorado Denver)Caroline Robert(Institut Gustave Roussy)Dirk Schadendorf(Essen University Hospital)Jessica C. Hassel(German Cancer Research Center)Wallace Akerley(Huntsman Cancer Institute)Alfons J.M. van den Eertwegh(Amsterdam UMC Location VUmc)Jose Lutzky(Sylvester Comprehensive Cancer Center)Paul Lorigan(The Christie Hospital)Julia Vaübel(Essen University Hospital)Gerald P. Linette(Washington University in St. Louis)David Hogg(Princess Margaret Hospital)Christian H. Ottensmeier(Hampton University)Célèste Lebbé(Saint Louis University Hospital)Christian PeschelIan Quirt(Princess Margaret Hospital)Joseph I. Clark(Loyola University Medical Center)Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)Jeffrey S. Weber(Moffitt Cancer Center)Jason TianMichael YellinGeoffrey NicholAxel Hoos(Bristol-Myers Squibb (United States))Walter J. Urba(Providence Portland Medical Center)

View via DOI Publisher page

Abstract

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

Immunotherapy and Immune Responses CAR-T cell therapy research vaccines and immunoinformatics approachesIpilimumabMetastatic melanomaMedicineMelanomaCytotoxic T cellAntigenOncologyCancer researchOverall survivalPeptide

MeSH terms

IpilimumabAntibodies, MonoclonalCombined Modality TherapyDouble-Blind MethodFemaleHumansMaleMelanomaMiddle AgedSkin NeoplasmsAntigens, CDTreatment OutcomeCancer VaccinesKaplan-Meier EstimateCTLA-4 Antigen